Breaking News Instant updates and real-time market news.

NVS

Novartis

$83.27

0.11 (0.13%)

05:36
07/18/17
07/18
05:36
07/18/17
05:36

Novartis backs FY17 revenue guidance of 'broadly in line with the prior year'

Novartis provided the following FY17 outlook: "We re-confirm our Group outlook as presented at the beginning of 2017. Group net sales in 2017 are expected to be broadly in line with the prior year, after absorbing the impact of generic competition, including the continued genericization of Gleevec/Glivec in the U.S. and Europe. From a divisional perspective, we expect net sales performance in 2017 to be as follows: Innovative Medicines: broadly in line with prior year, to a slight increase; Sandoz: broadly in line with prior year; Alcon: revised upward to low single digit growth. Group core operating income in 2017 is expected to be broadly in line with prior year to a low single digit decline. If mid-July exchange rates prevail for the remainder of 2017, the currency impact for the year would be negative 1 percentage point on net sales and negative 2 percentage points on core operating income."

  • 18

    Jul

NVS Novartis
$83.27

0.11 (0.13%)

07/14/17
LEER
07/14/17
NO CHANGE
Target $36
LEER
Outperform
Leerink sees significant optionality for AstraZeneca beyond MYSTIC trial
Leerink analyst Seamus Fernandez said he sees significant optionality for AstraZeneca (AZN) beyond the "mega-catalyst" of the MYSTIC trial in non-small cell lung cancer, as he believes several 2017 and 2018 readouts from underappreciated pipeline assets could lead to upside for the shares. If MYSTIC fails, Astra's "massive" SG&A spend gives it flexibility to mute the bottom-line impact. If it is successful, he believes potential acquirers such as Pfizer (PFE) or Novartis (NVS) could see "an attractive target to plunder," Fernandez tells investors. He keeps an Outperform rating and $36 price target on AstraZeneca ADRs.
07/13/17
SBSH
07/13/17
NO CHANGE
SBSH
Novartis vote bodes well for Kite and Juno, says at Citi
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
07/12/17
RHCO
07/12/17
NO CHANGE
Target $108
RHCO
Buy
bluebird bio recent weakness unwarranted, says SunTrust
SunTrust analyst Edward Nash views the weakness in bluebird bio (BLUE) shares since the FDA briefing document on Novartis' (NVSR) CAR T product candidate as unwarranted. The tone of the briefing document is neutral and emphasizes short-term toxicities observed in Novartis' studies and long-term safety concerns so that the Advisory Committee will be able to conduct a thorough discussion to determine the risk/benefit ratio, Nash tells investors in a research note. Further, he believes the data from Novartis and bluebird are not an apples-to-apples comparison and reminds investors of the "differentiated safety profile" that bluebird's bb2121 has demonstrated to date. He recommends buying bluebird on the recent selloff and reiterates a Buy rating on the name with a $108 price target.
07/10/17
JEFF
07/10/17
NO CHANGE
Target $121
JEFF
Buy
Jefferies ups Kite target to $121 on 'relatively benign' FDA docs
Jefferies analyst Biren Amin raised his price target for Kite Pharma (KITE) shares to $121 from $101 after the FDA posted briefing documents ahead of the July 12 committee meeting disusing Novartis' (NVS) CAR-T therapy CTL019. The documents for the first CAR-T therapy seem "relatively benign," Amin tells investors in a research note. The FDA's view of CAR-T therapies looks in-line with expectations, but the agency may require long-term follow-up of patients to assess for risk of secondary malignancies, Amin writes. He keeps a Buy rating on Kite Pharma. The stock in late morning trading is down 3% to $102.55.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,501.81

-9.86 (-0.65%)

11:04
11/20/18
11/20
11:04
11/20/18
11:04
Technical Analysis
Technical Take: Amazon.com hits highs of the session »

The shares of Amazon.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

OKTA

Okta

$47.47

-1.17 (-2.41%)

11:03
11/20/18
11/20
11:03
11/20/18
11:03
Hot Stocks
Okta continues expansion of API gateway partner ecosystem »

Okta announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 09

    Jan

AJG

Arthur J. Gallagher

$77.73

-0.6 (-0.77%)

11:02
11/20/18
11/20
11:02
11/20/18
11:02
Hot Stocks
Arthur J. Gallagher acquires JP Tech Insurance Services, terms not disclosed »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNR

Denbury Resources

$2.29

-0.155 (-6.34%)

11:00
11/20/18
11/20
11:00
11/20/18
11:00
Options
2-strike put buyers in Denbury Resources as shares drop 9.3% »

2-strike put buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
11/20/18
11/20
11:00
11/20/18
11:00
General news
Atlanta Fed's Q4 GDPNow estimate was cut to 2.5% »

Atlanta Fed's Q4…

DB

Deutsche Bank

$9.38

-0.39 (-3.99%)

, DNSKY

Danske Bank

$0.00

(0.00%)

10:56
11/20/18
11/20
10:56
11/20/18
10:56
Periodicals
Deutsche finds $150B of suspicious flows tied to Danske, WSJ reports »

Deutsche Bank's (DB)…

DB

Deutsche Bank

$9.38

-0.39 (-3.99%)

DNSKY

Danske Bank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NURO

NeuroMetrix

$0.98

-0.02 (-2.00%)

10:53
11/20/18
11/20
10:53
11/20/18
10:53
Hot Stocks
NeuroMetrix issued new U.S. patent for Quell wearable technology »

NeuroMetrix announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

X

U.S. Steel

$26.42

-0.86 (-3.15%)

10:50
11/20/18
11/20
10:50
11/20/18
10:50
Options
US Steel sees put buying as shares drop 4.4% »

US Steel sees put buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$5.98

-0.075 (-1.24%)

10:47
11/20/18
11/20
10:47
11/20/18
10:47
Periodicals
Snap soon to debut new, higher-priced Spectacles with two cameras, Cheddar says »

Snap is looking to debut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 28

    Nov

TLSA

Tiziana Therapeutics

$0.00

(0.00%)

10:45
11/20/18
11/20
10:45
11/20/18
10:45
Syndicate
Tiziana Therapeutics opens at $10.50, IPO priced at $9.90 »

Tiziana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BE

Bloom Energy

$14.00

-0.5 (-3.45%)

10:45
11/20/18
11/20
10:45
11/20/18
10:45
Conference/Events
Bloom Energy has a conference call hosted by JPMorgan »

JPMorgan Analyst Coster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$264.96

-4.32 (-1.60%)

10:42
11/20/18
11/20
10:42
11/20/18
10:42
Technical Analysis
Technical Take: SPDR S&P 500 ETF breaks back above $265 »

The SPDR S&P 500 ETF…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$264.96

-4.32 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$42.91

-1.51 (-3.40%)

10:40
11/20/18
11/20
10:40
11/20/18
10:40
Options
Put spreads in Morgan Stanley weekly options as shares fall to 52-week lows »

Put spreads in Morgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,478.00

-33.67 (-2.23%)

10:38
11/20/18
11/20
10:38
11/20/18
10:38
Technical Analysis
Technical Take: Amazon.com breaks back above $1500 »

The stock saw a deep low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 04

    Dec

BBY

Best Buy

$63.02

0.83 (1.33%)

10:31
11/20/18
11/20
10:31
11/20/18
10:31
Hot Stocks
Best Buy expects calendar shift to have positive impact of approx. 50bps in Q4 »

CFO Corie Barry says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

BAC

Bank of America

$26.99

-0.77 (-2.77%)

10:30
11/20/18
11/20
10:30
11/20/18
10:30
Options
Far downside puts opened in BofA »

Far downside puts opened…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

NVDA

Nvidia

$142.45

-2.21 (-1.53%)

10:23
11/20/18
11/20
10:23
11/20/18
10:23
Hot Stocks
Nvidia turns positive as Citron sees opportunity to buy »

Shares of Nvidia, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

WMT

Walmart

$94.27

-2.53 (-2.61%)

10:23
11/20/18
11/20
10:23
11/20/18
10:23
Downgrade
Walmart rating change  »

Walmart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$64.10

1.91 (3.07%)

10:21
11/20/18
11/20
10:21
11/20/18
10:21
Hot Stocks
Best Buy sees opportunities in connected health space »

CEO Hubert Joly says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

FXI

iShares China Large-Cap ETF

$40.19

-0.6 (-1.47%)

10:20
11/20/18
11/20
10:20
11/20/18
10:20
Options
Global selloff draws bullish vertical spread in China ETF »

Global selloff draws…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$143.52

-1.14 (-0.79%)

10:20
11/20/18
11/20
10:20
11/20/18
10:20
Periodicals
Citron Research says buying Nvidia »

Citron Research tweeted:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 10

    Dec

10:20
11/20/18
11/20
10:20
11/20/18
10:20
General news
U.S. credit ETFs are probing lows again »

U.S. credit ETFs are…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
11/20/18
11/20
10:17
11/20/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$57.00

-1.9 (-3.23%)

, CTT

CatchMark Timber

$8.89

-0.26 (-2.84%)

10:16
11/20/18
11/20
10:16
11/20/18
10:16
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…

HXL

Hexcel

$57.00

-1.9 (-3.23%)

CTT

CatchMark Timber

$8.89

-0.26 (-2.84%)

BBU

Brookfield Business Partners

$36.34

(0.00%)

NVTA

Invitae

$12.12

-0.66 (-5.16%)

MTEM

Molecular Templates

$4.59

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
11/20/18
11/20
10:16
11/20/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.